Scarica l'app Stockscreener
53.08
3.32%
-1.82
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio (NASDAQ:ANAB) Insider Sells $540,000.00 in Stock - MarketBeat
Risk Off: Can AnaptysBio Inc grow without external fundingJuly 2025 Trade Ideas & Safe Swing Trade Setups - baoquankhu1.vn
AnaptysBio, Inc. (ANAB) Stock Analysis: Unpacking the 23.71% Potential Upside for Investors - DirectorsTalk Interviews
Page not foundAirwhon - MarketBeat
AnaptysBio Details Q2 Royalty Spin, Jemperli Growth and ANB033 Celiac Data Coming in Q4 - Yahoo Finance
ANAB: Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline - TradingView
AnaptysBio stock hits 52-week high at $52.56 By Investing.com - Investing.com South Africa
Is AnaptysBio (ANAB) Still Attractively Priced After 242% One-Year Share Price Surge? - Yahoo Finance
(ANAB) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Market Trends: Is AnaptysBio Inc a momentum stockDollar Strength & Real-Time Stock Price Movement Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighShould You Buy? - MarketBeat
AnaptysBio Teases Q2 Split Into RoyaltyCo and Biopharma Spin, Flags Jemperli and Pipeline Catalysts - MarketBeat
AnaptysBio stock hits 52-week high at $52.56 - Investing.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte, Novartis - Barchart.com
Will AnaptysBio Inc. outperform its industry peers2025 Key Lessons & Growth Focused Entry Point Reports - mfd.ru
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Momentum Shift: Is AnaptysBio Inc in a consolidation phase2025 Dividend Review & Free Long-Term Investment Growth Plans - baoquankhu1.vn
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anaptys Announces Participation at Upcoming Investor Conferences - Sahm
AnaptysBio to participate in investor conferences. CEO to attend for discussions on immunology therapeutics. - Longbridge
Sentiment Review: Is GTIM in a long term uptrendJuly 2025 Macro Moves & Safe Entry Trade Reports - baoquankhu1.vn
Biotech Leader Eyes Spinoff Amid Massive Sales Surge - Investor's Business Daily
Federated Hermes Inc. Increases Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Responsive Playbooks and the ANAB Inflection - Stock Traders Daily
Inflation Data: Will BTCT benefit from rising consumer demandWeekly Stock Analysis & Verified Swing Trading Watchlist - baoquankhu1.vn
H.C. Wainwright lifts AnaptysBio stock target to $22, keeps Neutral - MSN
Can AnaptysBio Inc. reach all time highs this yearQuarterly Trade Summary & Daily Stock Trend Reports - mfd.ru
Bear Alert: Is AnaptysBio Inc undervalued by DCF analysisDollar Strength & Daily Stock Trend Reports - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
ANAPTYBIO INC (NASDAQ:ANAB) Offers High-Growth Momentum and a Bullish Technical Setup - ChartMill
Assessing AnaptysBio (ANAB) Valuation As Technical Strength Meets Improving Profitability Prospects - Sahm
CD122’s double whammy makes for intriguing target - BioWorld MedTech
Understanding the Setup: (ANAB) and Scalable Risk - Stock Traders Daily
Treasury Yields: Will AnaptysBio Inc benefit from geopolitical trendsJuly 2025 Recap & Expert Approved Trade Ideas - baoquankhu1.vn
Barclays Raises Price Target for AnaptysBio (ANAB) to $78.00 | A - GuruFocus
Did Big EPS, Revenue Jump and JPM Spotlight Just Shift AnaptysBio's (ANAB) Investment Narrative? - simplywall.st
ANAPTYSBIO INC (NASDAQ:ANAB) Shows Minervini Trend Template and High-Growth Momentum Alignment - Chartmill
AnaptysBio Shares Face Pressure Amid Insider Sale and Strategic Uncertainty - AD HOC NEWS
Market Leaders: Is AnaptysBio Inc stock a good dividend stock2025 Pullback Review & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Anaptysbio director Marquet sells $530k in shares By Investing.com - Investing.com Nigeria
AnaptysBio (NASDAQ:ANAB) Director Magda Marquet Sells 11,000 Shares - MarketBeat
Anaptysbio director Marquet sells $530k in shares - Investing.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Breakout Zone: Can AnaptysBio Inc generate free cash flowWeekly Stock Analysis & Real-Time Volume Trigger Notifications - baoquankhu1.vn
AnaptysBio (NASDAQ:ANAB) Stock Price Down 7.3%Time to Sell? - MarketBeat
Rally Mode: Is AnaptysBio Inc a momentum stock2025 Winners & Losers & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
AnaptysBio Teases 2026 Split, JEMPERLI Royalty Upside and Key Clinical Catalysts at JPM Conf - MarketBeat
ANAB: Separation into two focused entities targets value creation, with major clinical and royalty catalysts ahead - TradingView — Track All Markets
What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally - AOL.com
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2%Time to Buy? - MarketBeat
AnaptysBio stock: UBS reiterates Buy rating amid ongoing GSK litigation By Investing.com - Investing.com Canada
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock By Investing.com - Investing.com Nigeria
Royalty Pharma and Teva’s $500 million IL-15 deal boosts AnaptysBio stock - Investing.com Australia
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):